ClinConnect ClinConnect Logo
Search / Trial NCT06575101

Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management

Launched by TANG ZIREN · Aug 25, 2024

Trial Information

Current as of November 13, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how the body uses energy and nutrients in patients who have experienced cardiac arrest and are undergoing a treatment called Targeted Temperature Management (TTM). TTM helps protect the brain after a cardiac arrest by lowering the patient's body temperature. The researchers will look at how different temperatures (either 33 °C or 36 °C) affect the patients' energy use and nutrient metabolism. They are aiming to include about 40 patients who have been successfully resuscitated and are unconscious after their heart has started beating again.

To be eligible for this study, patients must be between 65 and 74 years old, have been admitted to the emergency department, and require advanced care in the intensive care unit. Participants in the trial can expect to have their energy expenditure and nutrient use measured at various points during their treatment. The study will also track their brain recovery over 28 days to see how well they are doing. This research may help improve care for future patients who experience cardiac arrest.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Be admitted to the emergency department of Beijing Chao-yang Hospital, Capital Medical University;
  • Successfully resuscitated, and are unconscious after restoration of spontaneous circulation (ROSC);
  • Be admitted to the intensive care unit (ICU) for advanced life support such as endotracheal intubation after restoration of spontaneous circulation (ROSC);
  • Accepted target temperature management (TTM) therapy after restoration of spontaneous circulation (ROSC);
  • Exclusion Criteria:
  • Age \> 18 years old;
  • Incomplete clinical data and loss of follow-up;
  • Traumatic brain injury or cerebrovascular accident revealed by computed tomography (CT);
  • Severe metabolic abnormalities are known: cachexia, thyroid dysfunction, and cancer;
  • Indirect calorimetry measurement is not possible such as sustained oxygen concentration \> 70%;
  • There were no signs of resuscitation at the time of admission;

About Tang Ziren

Tang Ziren is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on precision medicine, Tang Ziren specializes in the design and execution of clinical trials across various therapeutic areas, including oncology, cardiology, and neurology. The organization leverages cutting-edge technology and a robust network of clinical sites to ensure high-quality data collection and regulatory compliance. By fostering collaborative partnerships with healthcare professionals and institutions, Tang Ziren aims to accelerate the development of safe and effective treatments that address unmet medical needs.

Locations

Beijing, Beijing, China

Beijing, Beijing, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported